Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

Autor: King, Brett, Senna, Maryanne M., Mesinkovska, Natasha A., Lynde, Charles, Zirwas, Matthew, Maari, Catherine, Prajapati, Vimal H., Sapra, Sheetal, Brzewski, Pawel, Osman, Lawrence, Hanna, Sameh, Wiseman, Marni C., Hamilton, Colleen, Cassella, James
Zdroj: In Journal of the American Academy of Dermatology November 2024 91(5):880-888
Databáze: ScienceDirect
Externí odkaz: